Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI 02906, USA.
Expert Rev Anticancer Ther. 2011 Feb;11(2):151-60. doi: 10.1586/era.10.223.
Monoclonal antibodies have become an increasingly utilized treatment option for many hematological malignancies, including chronic lymphocytic leukemia (CLL). Ofatumumab is a second-generation fully human anti-CD20 monoclonal antibody that binds to the small extracellular loop of CD20, thereby producing complement-dependent cell lysis and antibody-mediated cell cytotoxicity in cells expressing CD20. Ofatumumab has shown efficacy in the treatment for relapsed or refractory CLL. This success has resulted in the recent US FDA approval of ofatumumab for the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab-based regimens. Major side effects of ofatumumab include infusion reactions, neutropenia and increased risk for infection. This article provides an overview of the current data supporting the use of ofatumumab for CLL and projects the future role of ofatumumab as monotherapy and combination therapy.
单克隆抗体已成为许多血液系统恶性肿瘤（包括慢性淋巴细胞白血病[CLL]）的一种越来越常用的治疗选择。奥法妥珠单抗是一种第二代完全人源抗 CD20 单克隆抗体，与 CD20 的小细胞外环结合，从而在表达 CD20 的细胞中产生补体依赖性细胞溶解和抗体介导的细胞细胞毒性。奥法妥珠单抗在治疗复发或难治性 CLL 方面显示出疗效。这一成功导致最近美国食品和药物管理局（FDA）批准奥法妥珠单抗用于治疗对氟达拉滨和阿仑单抗为基础的方案耐药的 CLL 患者。奥法妥珠单抗的主要副作用包括输注反应、中性粒细胞减少症和感染风险增加。本文概述了支持奥法妥珠单抗治疗 CLL 的现有数据，并预测了奥法妥珠单抗作为单药和联合治疗的未来作用。
